Effettuare il login Iscriviti gratis

Akari Therapeutics Plc Ret. sull'asset

Cos'è Ret. sull'asset di Akari Therapeutics Plc?

Ret. sull'asset di Akari Therapeutics Plc è -141.94%

Qual è la definizione di Ret. sull'asset?



Il rendimento delle attività indica quanto redditizie le attività di un'azienda stanno generando entrate. Viene calcolato dividendo il reddito netto per il patrimonio medio totale.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Ret. sull'asset di aziende nel Health Care settore su NASDAQ rispetto a Akari Therapeutics Plc

Cosa fa Akari Therapeutics Plc?

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Aziende con ret. sull'asset simili a Akari Therapeutics Plc